The Patent Finder

Relmada Therapeutics, Inc.

10 patents currently held · Updated Nov 15, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

2
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 8, 2027
    The maintenance fee for Multimodal abuse resistant and extended release opioid formulations (US 9,125,833) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol (US 10,624,887) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

PatentTitleStatus Expires Confidence
US 8,329,744Methods of preventing the serotonin syndrome and compositions for use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,125,833Multimodal abuse resistant and extended release opioid formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,687,496Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,534,446Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,624,887Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,364,430Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,607,407Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use
In force
 · High confidence
In forceHigh confidence
US 10,933,014Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,026,9543-Beta-Hydroxy-5-Alpha-Pregnan-20-One for Use in Medical Treatment
In force
 · High confidence
In forceHigh confidence
US 11,026,9533-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 10: 2 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited